FAQ: What Role Does a New Mechanism of Action Play in Your Prescribing Decisions of IBS-C Therapy?

Thank you Ardelyx for your support of this FAQ Video Module.

For years, the primary treatment options for irritable bowel syndrome with constipation (IBS-C) have been limited to secretagogues, offering varying doses and tolerability. However, a new mechanism of action (MOA) is now available, revolutionizing treatment choices for healthcare providers and patients alike. In this discussion, Kim Orleck, PA-C, from Atlanta Gastroenterology Associates, explores the triple-action MOA of this novel IBS-C therapy and how it enhances clinical decision-making.

This innovative therapy works by targeting the sodium-hydrogen exchanger isoform 3 (NHE3) on the apical surfaces of the small intestine and colon. By inhibiting NHE3, three key physiological effects occur. First, dietary sodium absorption is reduced, leading to increased luminal water content, which accelerates intestinal transit and softens stool consistency. Second, intestinal permeability is decreased, which helps to reduce abdominal pain. Lastly, visceral hypersensitivity is lowered, further alleviating the pain associated with IBS-C. These combined actions address multiple aspects of IBS-C pathophysiology, providing a minimally absorbed yet highly effective approach to symptom management.

With this exciting advancement, healthcare providers now have a novel treatment option that expands beyond traditional secretagogues, offering a new level of relief for patients struggling with IBS-C. To learn more, visit the GHAPP website for additional insights and expert perspectives on IBS-C management.